

Background

- Hand and Foot Syndrome (HFS) are common adverse effects in cancer patients undergoing treatment with specific chemotherapeutic agents, impact the quality of life and may necessitate dose reductions or treatment discontinuation.
- Topical prophylactic treatments, such as a cream containing urea, allantoin, vitamin E, pyridoxine, and arginine, have shown potential benefits in preventing these dermatologic toxicities separately.



Objective

Study evaluates the effectiveness of prophylactic use of a cream containing urea, allantoin, vitamin E, pyridoxine, and arginine in preventing HFS in cancer patients receiving culprit chemotherapy

Title:

Efficacy of Urea Cream with Allantoin, Vitamin E, Pyridoxine, and Arginine in treatment and prophylaxis of chemotherapy induced Hand and Foot syndrome

Authors:

Suyash Bharat¹, Priyal Savalia², Richa Tripathi¹

- 1. Medical Affairs, Institution-Zydus Lifesciences LTD, Gujarat, IND
- 2. Department of Medical Oncology, Kiran Hospital, Surat, Gujarat, IND



Methods

- ❖ A retrospective, observational study in cancer patients who were treated with chemotherapeutic agents known to cause HFS.
- Data was be collected retrospectively from Case Report Form (CRF) / medical records of patients treated between [January 2024-November 2024].
- ❖ Patients used Skix cream (Urea 12% w/w, L-Arginine, Vitamin E Acetate, Pyridoxine Hydrochloride and Allantoin) for 2 plus months and Grade of HFS was evaluated at base line and 2 follow-ups for usage of the cream using Grading system for HFS per the NCI Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.



Result

- ❖ In 35 patients, who received this cream, Most common cancer were GI cancer (15/35), Breast Cancer (11/35).
- ❖ 21 (60%) had preexisting HFS.
- ❖ From baseline to 1st Follow-Up, Patients on Skix, in state 0 (no HFS) have a high probability (64%) of remaining in state 0, while 28% chance of moving to state 1 (mild HFS).
- ❖ Patients in state 1 (mild HFS) have a 69% chance of remaining in state 1 and a 23% chance of moving to state 0. Patients in state 2 (moderate HFS) turned to lower grade in 89% cases.
- ❖ From 1st Follow-Up to 2nd Follow-Up, all patients in state 0 remain in state 0. 60% of Patients in state 1 became stage 0 and a 40% remained in same state. (TABLE)

TABLE

Chemotherapy related details			Number of observed transitions		
Capecitabine	20 (55.56%)		between adverse event grades		
•	` ,			Baseline to	First follow-up to
Liposomal doxorubicin	5 (13.89%)			first follow-up	second follow-up
Docetaxel	4 (11.42%)			(n=35)	(n=35)
Fluorouracil	4 (11.42%)		0→0	9	18
	` ,		0→1	4	0
Paclitaxel	2 (5.7%)		0→2	1	0
Number of Patients requiring Chemotherapy Dose Modifications		7 (19.4%)	1→0	8	9
			1→1	3	6
Number of Patients requiring rescue Medication for HFS		8 (22.2%)	1→2	1	0
			2→2	0	0
			2→1	8	2
(Gabapentin, Prega	balin)		2→0	1	0



Conclusions

- Based on this real-world data, use of a cream containing urea, allantoin, vitamin E, pyridoxine, and arginine shows promising results in preventing and treating Hand and Foot Syndrome (HFS) in cancer patients receiving HFSinducing drugs.
- The combination of these ingredients appears to provide a synergistic effect, reducing the incidence and severity of HFS.